Anthera Pharmaceuticals (ANTH) Stock Price, News & Analysis

Company Overview

Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) is a biopharmaceutical company focused on the development and commercialization of novel therapies for serious inflammatory and autoimmune diseases. Headquartered in Hayward, California, Anthera’s research and development efforts are centered on targeting key pathways involved in immune dysregulation. The company’s portfolio includes small-molecule and biologic candidates designed to address conditions with significant unmet medical needs.

Among Anthera’s leading product candidates is a spleen tyrosine kinase (SYK) inhibitor being evaluated for immune thrombocytopenia (ITP) and other autoimmune disorders characterized by aberrant B-cell signaling. In parallel, the company has advanced BLISIBIMOD, a selective BAFF-neutralizing peptide, into clinical studies for indications such as IgA nephropathy and systemic lupus erythematosus (SLE). These programs leverage Anthera’s proprietary expertise in immune modulation and its established manufacturing partnerships.

Since its inception, Anthera has conducted multiple Phase 2 and Phase 3 trials across North America, Europe and Asia, collaborating with academic medical centers and patient advocacy groups. The company’s strategic alliances facilitate global trial enrollment and bolster its regulatory strategy, with the goal of achieving timely approvals and broad patient access. Anthera’s business model also contemplates out-licensing opportunities to larger pharmaceutical partners for late-stage development and commercialization.

Anthera is led by a management team with deep experience in biopharmaceutical R&D, regulatory affairs and commercial operations. The board and executive officers bring together expertise from established life science companies, contributing to the company’s disciplined approach to clinical development and corporate governance. Through its targeted pipeline, Anthera aims to deliver new therapies that improve outcomes for patients living with debilitating autoimmune diseases.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 208 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ANTH Stock Analysis - Frequently Asked Questions

How were Anthera Pharmaceuticals' earnings last quarter?

Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) posted its earnings results on Monday, March, 5th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.82) by $0.09.

When did Anthera Pharmaceuticals' stock split?

Shares of Anthera Pharmaceuticals reverse split on Monday, May 1st 2017.The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

How do I buy shares of Anthera Pharmaceuticals?

Shares of ANTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Anthera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Anthera Pharmaceuticals investors own include Ocular Therapeutix (OCUL), Novavax (NVAX), Arena Pharmaceuticals (ARNA), Bristol Myers Squibb (BMY), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 3/05/2018
• Today: 7/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:ANTH
• CIK: 1316175
• Web: www.anthera.com
• Phone: (410) 350-1839
• Fax: 510-856-5597
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 1.82